Literature DB >> 3517271

Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology.

D A Goldmann, J D Klinger.   

Abstract

Pseudomonas cepacia, originally described as a plant pathogen, has emerged as an important cause of infection in altered hosts, particularly in the hospital setting. This organism's ability to survive and proliferate in a variety of solutions, medications, and even disinfectants and antiseptics has resulted in numerous clusters of common-source nosocomial infections. Many patients exposed to P. cepacia are merely colonized, but serious infections, including surgical and burn wound infections, bacteremia, meningitis, pneumonia, peritonitis, and urinary tract infections, are not rare. The virulence properties of this pathogen remain poorly characterized. Recently, P. cepacia has been reported in some cystic fibrosis centers as an increasingly frequent pulmonary pathogen. This trend has caused considerable concern because of reports of occasional cases of fulminant necrotizing pneumonia and bacteremia. Conversely, many patients with CF who become colonized with this organism have no ill effects. The epidemiology of P. cepacia in the CF population is unclear, but some patients probably acquire the organism from colonized siblings with CF. Circumstantial evidence suggests that the organism may also be acquired in the hospital. Treatment of infections is exceedingly difficult, particularly in patients with CF, because P. cepacia is resistant to a broad range of antibiotics.

Entities:  

Mesh:

Year:  1986        PMID: 3517271     DOI: 10.1016/s0022-3476(86)80749-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  47 in total

1.  The effects of purified 25-kDa lipase from a clinical isolate of Pseudomonas cepacia in the lungs of rats.

Authors:  M K Lonon; D E Woods; D C Straus
Journal:  Curr Microbiol       Date:  1992-08       Impact factor: 2.188

Review 2.  Advances in electronic-nose technologies developed for biomedical applications.

Authors:  Alphus D Wilson; Manuela Baietto
Journal:  Sensors (Basel)       Date:  2011-01-19       Impact factor: 3.576

Review 3.  Ten years of bacterial genome sequencing: comparative-genomics-based discoveries.

Authors:  Tim T Binnewies; Yair Motro; Peter F Hallin; Ole Lund; David Dunn; Tom La; David J Hampson; Matthew Bellgard; Trudy M Wassenaar; David W Ussery
Journal:  Funct Integr Genomics       Date:  2006-05-12       Impact factor: 3.410

4.  Enterococcus faecalis mammalian virulence-related factors exhibit potent pathogenicity in the Arabidopsis thaliana plant model.

Authors:  Ajay K Jha; Harsh P Bais; Jorge M Vivanco
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Pseudomonas cepacia in cystic fibrosis.

Authors:  D E Stableforth; D L Smith
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

6.  Pseudomonas infections in cystic fibrosis.

Authors:  R H George
Journal:  Arch Dis Child       Date:  1987-05       Impact factor: 3.791

7.  The Pseudomonas cepacia 249 chromosomal penicillinase is a member of the AmpC family of chromosomal beta-lactamases.

Authors:  R Proenca; W W Niu; G Cacalano; A Prince
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.

Authors:  D L Smith; L B Gumery; E G Smith; D E Stableforth; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

9.  Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources.

Authors:  L A Carson; O C Tablan; L B Cusick; W R Jarvis; M S Favero; L A Bland
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

Review 10.  Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health?

Authors:  A Holmes; J Govan; R Goldstein
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.